Current perspectives on neuroendocrine tumors
hLife, ISSN: 2949-9283, Vol: 2, Issue: 11, Page: 563-575
2024
- 2Citations
- 8Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Most Recent News
Research Findings from Shri Ramswaroop Memorial University Update Understanding of Neuroendocrine Cancer (Current perspectives on neuroendocrine tumors)
2024 NOV 18 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Daily -- Fresh data on neuroendocrine cancer are presented in a new
Review Description
Neoplasms arising from neuroendocrine cells form a heterogeneous group known as neuroendocrine tumors (NETs), which possess both endocrine and neural characteristics. These tumors can occur in various organs throughout the body, with the most prominent sites being the gastrointestinal tract, pancreas, and lungs. Despite their relatively low incidence, NETs have gained significant attention due to their unique biology and clinical behavior. This review intends to provide a widespread gestalt of the present perception of NETs, including their epidemiology, etiology, pathogenesis, classification, clinical presentation, diagnostic modalities, treatment options, and prognosis. Treatment strategies for NETs depend on tumor grade, stage, location, and functional status. Surgical resection remains the pillar of curative treatment for localized disease; on the other hand, systemic therapies take account of targeted therapies like tyrosine kinase inhibitors (TKIs), peptide receptor radionuclide therapy (PRRT), somatostatin analogs, and immunotherapy have shown promising results in advanced cases. In conclusion, this review provides an up-to-date summary of our current knowledge regarding neuroendocrine tumors. Further research is needed to better understand the underlying molecular mechanisms driving tumor development and progression. This will aid in developing novel therapeutic strategies targeting specific pathways involved in NET pathogenesis to improve patient outcomes.
Bibliographic Details
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know